Angiotensin Receptor Blockers: Pharmacology, Efficacy, and Safety

Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension

(2011) William B. White et al.   HYPERTENSION

The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure

(2011) George L. Bakris et al.   Journal of Clinical Hypertension

24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension

(2011) Y Lacourcière et al.   JOURNAL OF HUMAN HYPERTENSION

Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis

(2010) Bret R. Haymore et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study

(2010) Suzanne Oparil et al.   CLINICAL THERAPEUTICS

Pleiotropic Effects of Inhibitors of the RAAS in the Diabetic Population: Above and Beyond Blood Pressure Lowering

(2010) Haisam Ismail et al.   Current Diabetes Reports

Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension

(2010) Steven G. Chrysant et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pleiotropic Effects of Angiotensin Receptor Blockers: Addressing Comorbidities by Optimizing Hypertension Therapy

(2010) Peter P. Toth   Journal of Clinical Hypertension

Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the life study

(2010) Børge G. Nordestgaard et al.   Pharmacogenetics and Genomics

Has pharmacogenetics brought us closer to ‘personalized medicine’ for initial drug treatment of hypertension?

(2009) Donna K Arnett et al.   CURRENT OPINION IN CARDIOLOGY

Differences in pharmacology and their translation into differences in clinical efficacy – a comparison of the renin angiotensin blocking agents irbesartan and losartan

(2009) Peter Bramlage et al.   EXPERT OPINION ON PHARMACOTHERAPY

Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide

(2009) David A. Calhoun et al.   HYPERTENSION

Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients

(2009) Yoshio Matsui et al.   HYPERTENSION

Combination Therapy With Various Combinations of Aliskiren, Valsartan, and Hydrochlorothiazide in Hypertensive Patients Not Adequately Responsive to Hydrochlorothiazide Alone

(2009) Helmut Geiger et al.   Journal of Clinical Hypertension

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial

(2009) Roland E Schmieder et al.   JOURNAL OF HYPERTENSION

Oxidative Stress and Hypertension

(2009) David G. Harrison et al.   MEDICAL CLINICS OF NORTH AMERICA

The current state of RAAS blockade in the treatment of hypertension and proteinuria

(2009) Rigas G. Kalaitzidis et al.   Current Cardiology Reports

The Relationship Between the Plasma Concentration of Irbesartan and the Antihypertensive Response Is Disclosed by an Angiotensin II Type 1 Receptor Polymorphism: Results From the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial

(2008) L. Kurland et al.   AMERICAN JOURNAL OF HYPERTENSION

Left Ventricular Hypertrophy and Clinical Outcomes in Hypertensive Patients

(2008) L. M. Ruilope et al.   AMERICAN JOURNAL OF HYPERTENSION

Redox Signaling, Vascular Function, and Hypertension

(2008) Moo Yeol Lee et al.   ANTIOXIDANTS & REDOX SIGNALING

Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial

(2008) Sverre E. Kjeldsen et al.   BLOOD PRESSURE

Valsartan Improves Arterial Stiffness in Type 2 Diabetes Independently of Blood Pressure Lowering

(2008) Janaka Karalliedde et al.   HYPERTENSION

Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension

(2008) Daniel I. Feig et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?

(2008) Stephen C Benson et al.   JOURNAL OF HYPERTENSION

Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy

(2008) George Bakris et al.   KIDNEY INTERNATIONAL

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

(2008)   LANCET

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

(2008) Johannes FE Mann et al.   LANCET

Vascular cognitive impairment: current concepts and clinical developments

(2008) Paige Moorhouse et al.   LANCET NEUROLOGY

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy

(2008) J. Galle et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Uric Acid and Cardiovascular Risk

(2008) Daniel I. Feig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients

(2008) Kenneth Jamerson et al.   NEW ENGLAND JOURNAL OF MEDICINE